Barrington Research Research Analysts Lower Earnings Estimates for Henry Schein, Inc. (NASDAQ:HSIC)

Henry Schein, Inc. (NASDAQ:HSIC) – Barrington Research reduced their Q2 2024 earnings per share estimates for Henry Schein in a note issued to investors on Wednesday, May 8th. Barrington Research analyst M. Petusky now anticipates that the company will post earnings per share of $1.27 for the quarter, down from their prior estimate of $1.30. Barrington Research currently has a “Outperform” rating and a $92.00 target price on the stock. The consensus estimate for Henry Schein’s current full-year earnings is $5.07 per share. Barrington Research also issued estimates for Henry Schein’s Q3 2024 earnings at $1.31 EPS, Q4 2024 earnings at $1.42 EPS, FY2024 earnings at $5.10 EPS, Q1 2025 earnings at $1.14 EPS, Q2 2025 earnings at $1.34 EPS, Q3 2025 earnings at $1.39 EPS, Q4 2025 earnings at $1.59 EPS and FY2026 earnings at $6.00 EPS.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, May 7th. The company reported $1.10 EPS for the quarter, beating the consensus estimate of $1.01 by $0.09. The firm had revenue of $3.17 billion during the quarter, compared to the consensus estimate of $3.21 billion. Henry Schein had a net margin of 3.37% and a return on equity of 14.03%. The company’s quarterly revenue was up 3.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.21 earnings per share.

A number of other brokerages have also weighed in on HSIC. Evercore ISI lifted their target price on shares of Henry Schein from $79.00 to $83.00 and gave the company an “in-line” rating in a research note on Wednesday, February 28th. SVB Leerink began coverage on Henry Schein in a report on Monday, February 26th. They set a “market perform” rating and a $78.00 target price on the stock. JPMorgan Chase & Co. raised their target price on Henry Schein from $82.00 to $88.00 and gave the company an “overweight” rating in a research note on Wednesday, March 6th. UBS Group reduced their price target on Henry Schein from $82.00 to $80.00 and set a “neutral” rating on the stock in a research note on Wednesday. Finally, Leerink Partnrs reissued a “market perform” rating on shares of Henry Schein in a research report on Monday, February 26th. One research analyst has rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Henry Schein presently has a consensus rating of “Hold” and a consensus target price of $81.73.

Henry Schein Stock Performance

Shares of HSIC stock opened at $73.44 on Thursday. The firm has a market capitalization of $9.44 billion, a price-to-earnings ratio of 23.31, a PEG ratio of 1.68 and a beta of 0.87. The stock has a fifty day moving average of $72.95 and a 200 day moving average of $72.35. Henry Schein has a 52 week low of $60.01 and a 52 week high of $82.63. The company has a quick ratio of 1.00, a current ratio of 1.67 and a debt-to-equity ratio of 0.45.

Insider Transactions at Henry Schein

In other Henry Schein news, CEO Bradford C. Connett sold 6,430 shares of the stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $74.28, for a total value of $477,620.40. Following the sale, the chief executive officer now owns 73,108 shares in the company, valued at $5,430,462.24. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, CEO Bradford C. Connett sold 6,430 shares of the company’s stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $74.28, for a total transaction of $477,620.40. Following the transaction, the chief executive officer now directly owns 73,108 shares of the company’s stock, valued at approximately $5,430,462.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Vice Chairman James P. Breslawski sold 2,907 shares of the company’s stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $74.37, for a total transaction of $216,193.59. Following the transaction, the insider now owns 209,562 shares in the company, valued at approximately $15,585,125.94. The disclosure for this sale can be found here. Company insiders own 1.14% of the company’s stock.

Institutional Trading of Henry Schein

Hedge funds and other institutional investors have recently bought and sold shares of the stock. McGlone Suttner Wealth Management Inc. acquired a new position in shares of Henry Schein during the 4th quarter valued at about $39,000. Neo Ivy Capital Management acquired a new stake in shares of Henry Schein during the 3rd quarter worth approximately $46,000. Mather Group LLC. acquired a new stake in shares of Henry Schein during the 1st quarter worth approximately $97,000. Covestor Ltd lifted its holdings in Henry Schein by 22.8% in the third quarter. Covestor Ltd now owns 1,367 shares of the company’s stock valued at $102,000 after acquiring an additional 254 shares during the last quarter. Finally, Palisade Asset Management LLC purchased a new position in Henry Schein in the first quarter worth approximately $113,000. 96.62% of the stock is owned by institutional investors and hedge funds.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.